REZOLUTE, INC. Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount
REZOLUTE, INC. (RZLT) had Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount of $0 as of 2021-06-30, per its 10-K filed 2021-09-15.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount · last filed 2021-09-15
- 2021-06-30: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
- 2020-06-30: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
- 2019-06-30: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
- 2018-06-30: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
| Period end | Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount |
|---|---|
| 2021-06-30 | $0.00 10-K · filed 2021-09-15 |
| 2020-06-30 | $0.00 10-K · filed 2021-09-15 |
| 2019-06-30 | $0.00 10-K · filed 2020-10-13 |
| 2018-06-30 | $0.00 10-K · filed 2019-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |